Dr. Marina Bibikova has joined AnchorDx as Chief Scientific Officer. AnchorDx is a world-leading producer of cancer screening and early detection systems (CSO). She will be in charge of developing cancer early detection technologies, global IVD registrations, strategic relationships with leading international companies, international patent strategy, and global commercialization acceleration. The Board of Directors of AnchorDx values Dr. Bibikova’s abilities and has stated that internationalisation of technology, goods, and marketing are the company’s next main goals, all of which are competitive advantages. AnchorDx’s worldwide positioning and strategy implementation will benefit greatly from Dr. Bibikova’s solid platform, IVD product development, and registration experience.
“I worked with Marina at Illumina for 15 years, during which time we co-authored more than 40 academic papers. She has developed multiple cutting-edge technologies and products, such as the Illumina Infinium Human Methylation 450 BeadChip (450 k) array — one of the most cost-effective ways to analyze DNA methylation in the human genome, which targets 96% of CpG islands and covers more than 450,000 CpG sites. Marina’s scientific spirit and excellent leadership skills in technology and product development align excellently with AnchorDx’s values. We believe that with Marina’s appointment, the overseas registration of our products will accelerate as well as global business development to help AnchorDx achieve more technological breakthroughs in the early tumour detection industry,” mentioned Dr. Jian-Bing Fan, CEO and Founder of AnchorDx.
Dr. Bibikova is a global pioneer in the genomics business with over 25 years of expertise. She has authored more than 70 scholarly publications, possesses six international patents, and has created a number of ground-breaking genetic testing tools and products. Dr. Bibikova spent over 20 years at Illumina as a Principal Scientist, where she was responsible for the development of both Research and IVD products in the areas of genotyping, gene expression profiling, and DNA methylation analysis. She feels honored to be a part of and collaborate with such a bright group of scientists on the development of a revolutionary cancer diagnostic tool.
Dr. Bibikova spearheaded the 510(K) submissions for the Illumina MiSeqDx sequencer, which was the first in vitro diagnostic next-generation sequencing (NGS) device to be cleared by the US FDA, and has since received EU CE-IVD certification as well as China NMPA certification. It laid the groundwork for future sequencing platforms, such as the NextSeq 550Dx, to be successfully registered.
Source: PR Newswire
